Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3Howard I. Scher, Andrew J. Armstrong, Michael J. Morris et al.|Journal of Clinical Oncology|2016Cited by 1.6k
Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 StudyPhilip W. Kantoff, Nicholas J. Vogelzang, Susan Halabi et al.|Journal of Clinical Oncology|1999Cited by 893
Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate CancerSusan Halabi, Nicholas J. Vogelzang, Philip W. Kantoff et al.|Journal of Clinical Oncology|2003Cited by 678
Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583)Eric J. Small, Nicholas J. Vogelzang, Susan Halabi et al.|Journal of Clinical Oncology|2004Cited by 502
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY StudyAndrew J. Armstrong, Daniel J. George, Susan Halabi et al.|Journal of Clinical Oncology|2019Cited by 364